QL Biopharm has successfully concluded a B+ round of financing, securing nearly 200 million, with CEC Capital serving as the exclusive financial advisor.

This innovative platform specializes in recombinant protein drugs for metabolic diseases.

QL Biopharm announces the completion of a nearly 200 million B+ round of financing. IMEIK and China US Green Fund led this financing round, with significant contributions from major investors such as Grandway Capital, Chengdu Capital Group, and Kinsight Capital. Existing shareholder Bluerun Ventures continues to increase its investment.

CEC Capital exclusively acted as the financial advisor for this funding round.

The funds raised in this round will primarily be allocated to advancing the clinical trial progress of the First-in-class and Biosimilar pipelines. QL Biopharm's production facility is on the verge of completion and is set to become operational. With the successful conclusion of this round of financing, the participation of institutions like IMEIK and China US Green Fund will provide substantial support for the subsequent implementation of QL Biopharm's projects and the expansion of markets both domestically and internationally.